<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251962</url>
  </required_header>
  <id_info>
    <org_study_id>0489-19-TLV</org_study_id>
    <nct_id>NCT04251962</nct_id>
  </id_info>
  <brief_title>Role of Opioids in Epidural Solutions</brief_title>
  <official_title>The Role of Epidural Opioids in Pain Management After Abdominal Surgery in Adult Patients - a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Israel Society of Anesthesiologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is unclear whether addition of opioids to epidural solutions for postoperative analgesia
      is beneficial. In this multicenter randomized double-blinded trial, we aim to test the
      primary hypothesis that epidural solutions containing only bupivacaine are as effective as
      solutions containing both bupivacaine and fentanyl in promoting analgesia in patients
      recovering from open abdominal surgery. We also aim to assess the incidence of
      epidural-induced hypotension, the difference in patient-reported opioid side-effects between
      the two groups. If we demonstrate no clinically important difference between the two
      interventions, clinicians will be able to substantially reduce the amount of opioids patients
      receive during their postoperative recovery, and potentially decrease the associated high
      incidence of opioid adverse effects in post-surgical patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative analgesia</measure>
    <time_frame>48 postoperative hours</time_frame>
    <description>A joint outcome of the difference in average pain score and a ratio of opioid consumption (in mg morphine equivalents) between the 2 study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant postoperative hypotension</measure>
    <time_frame>48 postoperative hours</time_frame>
    <description>Number of participants experiencing a composite of use of IV fluid boluses prescribed for hemodynamic support; sympathomimetic drugs administration; and holding or early discontinuation of the epidural infusion in order to recover blood pressure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recovery of gastrointestinal function</measure>
    <time_frame>Throughout the postoperative hospital stay, up to 30 days</time_frame>
    <description>Time to first postoperative bowel movement</description>
  </other_outcome>
  <other_outcome>
    <measure>Opioid-related side effects</measure>
    <time_frame>48 postoperative hours</time_frame>
    <description>A composite of opioid-related side-effects as measured by the Opioid-Related Symptom Distress Scale (OR-SDS) questionnaire (higher scores represent more side-effects and related distress, scores are given on multiple dimensions)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidural solution containing 0.1% bupivaacaine in normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine + Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidural solution containing 0.1% bupivacaine and 3 mcg/ml of fentanyl in normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>epidural solution containing bupivacaine 0.1% in normal saline</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine + Fentanyl</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline</description>
    <arm_group_label>Bupivacaine + Fentanyl</arm_group_label>
    <other_name>Beatryl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. 18-85 years old

          3. Undergoing open abdominal surgery (including colorectal, intestinal, gastric,
             pancreatic, hepatobiliary, urological, or gynecological surgery)

          4. For which a clinical decision has been made to provide epidural analgesia
             preoperatively and extending to the post-operative period

          5. Anticipated hospitalization of at least 2 nights

        Exclusion Criteria:

          1. Known allergy to bupivacaine or fentanyl

          2. Chronic liver disease, defined as cirrhosis, portal hypertension, or variceal bleeding

          3. Patients under chronic alpha-blocking agents for hypertension

          4. Clinical contraindications to epidural introduction, as judged by the anesthesia
             provider (thrombocytopenia, un-interrupted anticoagulation, clinically-significant
             atrio-ventricular conduction block, etc.)

          5. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barak Cohen, MD</last_name>
    <phone>+972-52-7360368</phone>
    <email>barakc@tlvmc.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Orr Goren, MD</last_name>
    <phone>+972-52-7360330</phone>
    <email>goren.orr@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Anesthesia, Pain and Critical Care, Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Barak Cohen, MD</last_name>
      <phone>+972-52-7360368</phone>
      <email>barakc@tlvmc.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Orr Goren, MD</last_name>
      <phone>+972-52-7360330</phone>
      <email>goren.orr@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Barak Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Orr Goren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Senior Anesthesiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

